Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

Mon, 01st Jun 2020 11:16

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Monday and not separately reported by Alliance News:

----------

Fuller Smith & Turner PLC - pubs - To issue commercial paper under Covid Corporate Financing facility for initial sum of GBP100 million, allowing GBP155 million revolving credit facility to remain undrawn. Placed 96% of employees on furlough, while executives and board members volunteered for pay reduction.

----------

Arricano Real Estate PLC - property - All five shopping centres in Ukraine open with effect on Saturday last week, as restrictions by local authorities on access to shopping centres lifted. However, food courts, cinema and entertainment centres will remain closed.

----------

Topps Tiles PLC - tile retail - To sale and leaseback head office in Enderby, Leicester, to UK Warehouse Properties Ltd for GBP18.1 million. Proceeds expected to strengthen group's financial position in the face of the Covid-19 crisis.

----------

Mattioli Woods PLC - wealth management - Annual revenue to be ahead of GBP58.5 million reported the year before. Profit to be ahead of management expectations. Directors to take 50% reduction in salaries and fees until end of June, while chief executive officer takes no salary at all. Group in strong financial position following the acquisition of Hurley Partners in March.

----------

Motif Bio PLC - cash shell - Remains in negotiations with several reverse takeover candidates in the healthcare sector, as the pandemic creates new opportunities for healthcare firms.

----------

CloudCall Group PLC - communications - Expects to have enough cash to fund it through period of macroeconomic uncertainty. Continues to report ongoing challenges within the broader marketplace, which has near-term impact on the sales pipeline. Year-to-date sales bookings from new customers 28% less than same period the year before.

----------

Zoetic International PLC - cannabidiol - Signs distribution agreement with partner BettermentRS to market tobacco-alternative Chill products to its network of outlets. Rollout of Chill brand delayed by pandemic, as many retail outlets closed on lockdown restrictions.

----------

MJ Hudson Group PLC - asset management - Reports strong sales activity and levels of client work during lockdown period. Confident in achieving profit for year ending June 30 in line with market expectations, despite revenue disruption due to the lack of new fund launch activity.

----------

Marshall Motor Holdings PLC - cars - Trading significantly ahead of UK market in first quarter of 2020. As lockdown eases, group gradually expanded its offering of aftersales services, with initial demand encouraging. Furloughed 90% of employees during lockdown period as many stores closed. To post a pretax loss for the first half of 2020.

----------

Braveheart Investment Group PLC - investments - Subsidiary Paraytec Ltd to launch project with University of Sheffield to develop a rapid test for Covid-19 test, which will utilise highly sensitive light-based detection system coupled with a molecular "affinity" device to capture Covid-19 virus particles. Paraytec to own all foreground intellectual property generated by the project.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
5 May 2020 10:58

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Read more
5 May 2020 09:17

Motif Bio raises ?0.65m as it hunts for reverse takeover opportunity

(Sharecast News) - Motif Bio, which has been reclassified as an AIM rule 15 cash shell, has raised a total of ?0.65m before expenses via a placing, it announced on Tuesday, through the issue of 162,500,000 ordinary shares with an institutional investor at a price of 0.4p each.

Read more
4 May 2020 15:42

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

Read more
14 Apr 2020 17:12

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Read more
19 Mar 2020 14:51

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Read more
18 Mar 2020 15:33

Motif Bio struggling to find reverse takeover opportunity

(Sharecast News) - Motif Bio updated the market on its corporate developments on Wednesday, having been reclassified as an AIM rule 15 cash shell.

Read more
28 Jan 2020 11:31

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Read more
26 Nov 2019 18:15

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Read more
18 Nov 2019 13:50

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Read more
11 Nov 2019 09:52

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Read more
11 Nov 2019 09:40

Motif Bio reaches settlement with former clinical research organisation

(Sharecast News) - Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.

Read more
25 Oct 2019 17:34

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Read more
24 Oct 2019 16:05

Motif Bio announces US Army-funded evaluation of 'iclaprim'

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.

Read more
24 Oct 2019 12:01

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.